Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2009-08-24 Regulatory Filings
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
PCC Effective In Reducing Illness in Athletes 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 25 August 2009 from Probiomics Limited, reporting positive clinical trial results for their product PCC®. It discusses study details, outcomes, and marketing implications. There are no financial statements, regulatory filings, or detailed financial data. The document is relatively short (3498 characters) and reads as a news release or announcement rather than a formal financial or regulatory report. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement of clinical trial results relevant to investors and the market, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous company announcement that does not fit other specific categories.
2009-08-24 English
Preliminary Final Report 20 pages ?Kb
Annual Report Classification · 95% confidence The document is titled 'APPENDIX 4E' and is addressed to the Australian Stock Exchange, indicating it is a formal financial announcement. It covers a full twelve-month reporting period from 1 July 2008 to 30 June 2009, which aligns with a fiscal year. The content includes detailed financial statements such as the Income Statement, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement, and Notes to the Financial Statements. It also contains management commentary on results, business strategy, and accounting policies. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of comprehensive financial data and analysis for a full fiscal year strongly indicates this is an Annual Report. The Australian Appendix 4E is typically a preliminary final report for the full year, which is a form of annual report disclosure. Therefore, the document should be classified as an Annual Report (10-K equivalent). FY 2009
2009-08-17 English
Extension of Convertible Notes 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Probiomics Limited regarding the extension of convertible notes by the note holder. It mentions a financing instrument (convertible notes) and an extension of their maturity. The document is brief (1123 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is an update on a financing activity, specifically about capital structure changes. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2009-08-04 English
Resignation of CEO 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is a short announcement dated 31 July 2009 from Probiomics Limited addressed to the Australian Stock Exchange Companies Announcements Office. The key content is the resignation of the CEO, Mr. Stuart Craig, effective immediately. There is no financial data, no discussion of financial results, no mention of reports or filings, and the document is brief (1145 characters). This fits the description of an announcement of changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG).
2009-07-30 English
Quarterly Cashflow Report 6 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C – Quarterly cash report' and is addressed to the ASX Companies Announcements Office. It contains detailed quarterly cash flow information, including operating, investing, and financing cash flows, as well as reconciliation of cash and compliance statements. The report is for the quarter ended 30 June 2009. The Appendix 4C is a standard quarterly cash flow report required by the ASX for entities admitted on the basis of commitments. The document is 8165 characters long, which is substantive and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. Q4 2009
2009-07-20 English
Section 708A(6) Notice and Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a notice from Probiomics Limited dated 26 May 2009, announcing the completion of a private placement of shares and the issuance of shares upon conversion of convertible notes. It references compliance with subsection 708A(5)(e) and (6) of the Corporations Act 2001 (Cth), which relates to disclosure exemptions for securities issued without a prospectus. The document includes an Appendix 3B, which is a standard ASX form for new issue announcements, application for quotation of additional securities, and agreement. The content focuses on the issuance of new shares, options, and related securities, detailing the number, class, terms, and purpose of the securities issued. There are no financial statements, management discussion, or earnings data present. The document is regulatory in nature, announcing capital raising and share issuance activities, and includes the official Appendix 3B form required by the ASX for such transactions. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2009-05-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.